Novartisās drug to treat rare kidney disease gets USFDA approvalĀ
Switzerlandās Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of.
Drugs
Health
Pharma
Drugs
Health
Pharma
Denmarkās Pharmacosmos to buy G1 Therapeutics for $405 million
Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.
Drugs
Health
Pharma
Franceās Servier gets FDA green light for oral drug to treat brain cancer
Servier Pharmaceuticals, the US arm of a French pharmaceutical company, got approval from the US drug regulator for a once-daily pill to treat.
Drugs
Health
Pharma
US regulator allows GSKās endometrial cancer therapy for expanded use
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plcās endometrial cancer drug.
Drugs
Health
Pharma
Adaptimmuneās therapy to treat rare form of cancer gets USFDA nod
UK-based biopharmaceutical company, Adaptimmune Therapeutics Plc, got FDA approval for its cell therapy for treating a rare form of cancer.
Drugs
Health
Pharma
USFDA gives nod to Janssen Research’s blood cancer therapyĀ
The US Food and Drug Administration has approved the Darzalex Faspro combination drug therapy of Janssen Research and Development for treating blood cancer.
Drugs
Health
Pharma
FDA issues warning over weight-loss drug overdose, dosing errors
Overdose of weight-loss drugs and dosing errors by patients and healthcare providers have led to adverse events, including hospitalisation, the USFDA warned.
Drugs
Health
Pharma
Novo Nordiskās Wegovy gets UK regulator nod to treat heart risks
The UKās Medicines and Healthcare products Regulatory Agency has approved Novo Nordiskās weight-loss drug to cut the risk of obesity and adults suffering.
Drugs
Health
Pharma
FDA declines approval for Novo Nordiskās diabetic medicine
Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.
Drugs
Health
Pharma
FDA rejects Daiichi, Merck, antibody-drug conjugate application
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.